Clinical utility of nivolumab in the treatment of advanced melanoma

Ramsey Asmar,1 Jessica Yang,1 Richard D Carvajal1,2 1Department of Medicine, College of Physicians and Surgeons, 2Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA Abstract: Melanomas are highly immunogenic tumors that evade the immune system by exploiting innate c...

Full description

Bibliographic Details
Main Authors: Asmar R, Yang J, Carvajal RD
Format: Article
Language:English
Published: Dove Medical Press 2016-02-01
Series:Therapeutics and Clinical Risk Management
Subjects:
Online Access:https://www.dovepress.com/clinical-utility-of-nivolumab-in-the-treatment-of-advanced-melanoma-peer-reviewed-article-TCRM
id doaj-1808ed0704f7490b85ab6103fa2d3b34
record_format Article
spelling doaj-1808ed0704f7490b85ab6103fa2d3b342020-11-25T01:01:57ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2016-02-012016Issue 131332525762Clinical utility of nivolumab in the treatment of advanced melanomaAsmar RYang JCarvajal RDRamsey Asmar,1 Jessica Yang,1 Richard D Carvajal1,2 1Department of Medicine, College of Physicians and Surgeons, 2Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA Abstract: Melanomas are highly immunogenic tumors that evade the immune system by exploiting innate checkpoint pathways, rendering effector T-cells anergic. The immunotherapeutic approach of checkpoint inhibition can restore and invigorate endogenous antitumor T-cell responses and has become an important treatment option for patients with advanced melanoma. The CTLA-4 inhibitor ipilimumab and the PD-1 inhibitors nivolumab and pembrolizumab have been shown to induce durable responses and improve overall survival in metastatic, refractory melanoma. Optimization and validation of pretreatment biomarkers to predict response to these agents is a crucial area of ongoing research. Combination immunotherapy has recently demonstrated superior response rates compared to monotherapy; further investigation is needed to refine combinatorial strategies. Keywords: nivolumab, immune checkpoint inhibitors, PD-1, melanomahttps://www.dovepress.com/clinical-utility-of-nivolumab-in-the-treatment-of-advanced-melanoma-peer-reviewed-article-TCRMnivolumabimmune checkpoint inhibitorsPD-1melanoma
collection DOAJ
language English
format Article
sources DOAJ
author Asmar R
Yang J
Carvajal RD
spellingShingle Asmar R
Yang J
Carvajal RD
Clinical utility of nivolumab in the treatment of advanced melanoma
Therapeutics and Clinical Risk Management
nivolumab
immune checkpoint inhibitors
PD-1
melanoma
author_facet Asmar R
Yang J
Carvajal RD
author_sort Asmar R
title Clinical utility of nivolumab in the treatment of advanced melanoma
title_short Clinical utility of nivolumab in the treatment of advanced melanoma
title_full Clinical utility of nivolumab in the treatment of advanced melanoma
title_fullStr Clinical utility of nivolumab in the treatment of advanced melanoma
title_full_unstemmed Clinical utility of nivolumab in the treatment of advanced melanoma
title_sort clinical utility of nivolumab in the treatment of advanced melanoma
publisher Dove Medical Press
series Therapeutics and Clinical Risk Management
issn 1178-203X
publishDate 2016-02-01
description Ramsey Asmar,1 Jessica Yang,1 Richard D Carvajal1,2 1Department of Medicine, College of Physicians and Surgeons, 2Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA Abstract: Melanomas are highly immunogenic tumors that evade the immune system by exploiting innate checkpoint pathways, rendering effector T-cells anergic. The immunotherapeutic approach of checkpoint inhibition can restore and invigorate endogenous antitumor T-cell responses and has become an important treatment option for patients with advanced melanoma. The CTLA-4 inhibitor ipilimumab and the PD-1 inhibitors nivolumab and pembrolizumab have been shown to induce durable responses and improve overall survival in metastatic, refractory melanoma. Optimization and validation of pretreatment biomarkers to predict response to these agents is a crucial area of ongoing research. Combination immunotherapy has recently demonstrated superior response rates compared to monotherapy; further investigation is needed to refine combinatorial strategies. Keywords: nivolumab, immune checkpoint inhibitors, PD-1, melanoma
topic nivolumab
immune checkpoint inhibitors
PD-1
melanoma
url https://www.dovepress.com/clinical-utility-of-nivolumab-in-the-treatment-of-advanced-melanoma-peer-reviewed-article-TCRM
work_keys_str_mv AT asmarr clinicalutilityofnivolumabinthetreatmentofadvancedmelanoma
AT yangj clinicalutilityofnivolumabinthetreatmentofadvancedmelanoma
AT carvajalrd clinicalutilityofnivolumabinthetreatmentofadvancedmelanoma
_version_ 1715872428671893504